IP Library Patent Application 12262536
Patent Application
App. No. 12/262,536

Islet Cells from Human Embryonic Stem Cells

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/262,536
Abstract

This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.

Claims (11)

1 . A system for generating insulin expressing cells comprising a) a first in vitro population of cells comprising human embryonic stem cells; and b) a second isolated cell population comprising progeny of a portion of the first population of cells, wherein the progeny express insulin c-peptide.

2 . The system of claim 1 , wherein the first and second populations of cells are contained in separate containers.

3 . The system of claim 1 , wherein the second population of cells is contained in a device comprising a semi-permeable membrane.

4 . The system of claim 1 , wherein the first population of cells is genetically modified.

5 . The system of claim 1 , wherein the second population of cells is genetically modified.

6 . A system for generating gut endoderm cells comprising a) a first in vitro population of cells comprising human embryonic stem cells; and b) a second cell population comprising progeny of a portion of the first population of cells, wherein the progeny express Sox17, HNF1a and HNF3P.

7 . The system of claim 6 , wherein the first and second populations of cells are contained in separate containers.

8 . The system of claim 6 , wherein the first population of cells is genetically modified.

9 . The system of claim 6 , wherein the second population of cells is genetically modified.

10 . A system for generating insulin expressing cells comprising a) a first in vitro population of cells which express stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4), and markers detectable using antibodies designated Tra-1-60 and Tra-1-81; and b) a second isolated cell population comprising progeny of a portion of the first population of cells, wherein the progeny express insulin c-peptide.

11 . A system for generating gut endoderm cells comprising a) a first in vitro population of cells which express stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4) and markers detectable using antibodies designated Tra-1-60 and Tra-1-81; and b) a second cell population comprising progeny of a portion of the first population of cells, wherein the progeny express Sox17, HNF1α and HNF3p.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: INOKUMA, MARGARET S.; FISK, GREGORY J.
To: GERON CORPORATION
Reel/Frame 040961/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031536/0130 →